Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance
- PMID: 32931618
- DOI: 10.1111/apt.16080
Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance
Abstract
Background: Body composition may be modified after improvement of portal hypertension (PHT) by transjugular intrahepatic portosystemic shunt (TIPSS) insertion.
Aims: To evaluate changes in body composition following TIPSS placement, their relationship with radiological TIPSS patency and function, and the predictive value of these parameters METHODS: We retrospectively included 179 patients with cirrhosis who underwent TIPSS placement in our centre for severe PHT from 2011 to 2017. CT scan-based surveillance was performed at baseline, 1-3 (M1-M3) and 6 months (M6).
Results: The median model for end-stage liver disease (MELD) score was 11.4 (8.8-15.1) and Child-Pugh score 8 (7-9). Only the MELD score (HR 1.14, 95% CI 1.08-1.20) and sarcopenia assessed by transversal right psoas muscle thickness at the umbilical level/height (TPMPT/height) (HR 0.86, 95% CI 0.79-0.96) were independently associated with 6-month mortality on multivariate analysis. After TIPSS insertion, TPMT/height increased from 19 mm/m (baseline) to 19.6 mm/m (M1-M3, P = 0.004) and 21.1 mm/m (M6, P < 0.0001). The improvement and its extent were dependent on the radiological patency and dysfunction of TIPSS. Subcutaneous fat surface (SCFS) increased from 183.4 to 193 cm2 (P < 0.0001) and 229.8 cm2 (P < 0.0001), respectively. We observed a decrease in visceral fat surface (VFS) between baseline and M1-M3 (163.5-140.5 cm2 [P < 0.0001]), but not between M1-M3 and M6 (140.5-141.2 cm2 [P = 0.9]). SCFS and VFS did not seem to be modified by radiological TIPSS patency and dysfunction.
Conclusions: Sarcopenia is independently associated with 6-month outcome and improves after TIPSS placement, together with an inverse evolution of subcutaneous and visceral fat. TIPSS not only treats PHT but also improves body composition.
© 2020 John Wiley & Sons Ltd.
Comment in
-
Letter: TIPSS improves muscle mass indices in patients with cirrhosis and severe portal hypertension - authors' reply.Aliment Pharmacol Ther. 2021 Jan;53(1):199-200. doi: 10.1111/apt.16154. Aliment Pharmacol Ther. 2021. PMID: 33333598 No abstract available.
-
Letter: TIPSS and reversal of sarcopenia.Aliment Pharmacol Ther. 2021 Jan;53(1):210. doi: 10.1111/apt.16129. Aliment Pharmacol Ther. 2021. PMID: 33333603 No abstract available.
-
Letter: TIPSS is a promising therapy for sarcopenia in cirrhosis.Aliment Pharmacol Ther. 2021 Jan;53(1):209. doi: 10.1111/apt.16128. Aliment Pharmacol Ther. 2021. PMID: 33333606 No abstract available.
-
TIPSS and reversal of sarcopenia, and TIPSS is a promising therapy for sarcopenia in cirrhosis-Authors' reply.Aliment Pharmacol Ther. 2021 Jan;53(1):211-212. doi: 10.1111/apt.16152. Aliment Pharmacol Ther. 2021. PMID: 33333608 No abstract available.
-
Letter: TIPSS improves muscle mass indices in patients with cirrhosis and severe portal hypertension.Aliment Pharmacol Ther. 2021 Jan;53(1):198. doi: 10.1111/apt.16127. Aliment Pharmacol Ther. 2021. PMID: 33333611 No abstract available.
-
Letter: the improvement of sarcopaenia after TIPSS might result from survivor bias.Aliment Pharmacol Ther. 2021 Mar;53(5):676. doi: 10.1111/apt.16255. Aliment Pharmacol Ther. 2021. PMID: 33566400 No abstract available.
-
Letter: the improvement of sarcopenia after TIPSS might result from the survivor bias-authors' reply.Aliment Pharmacol Ther. 2021 Mar;53(5):677-678. doi: 10.1111/apt.16274. Aliment Pharmacol Ther. 2021. PMID: 33566422 No abstract available.
-
Letter: the diagnostic value of ultrasound-based versus CT-based sarcopenia measurement in cirrhosis.Aliment Pharmacol Ther. 2023 Mar;57(5):591-592. doi: 10.1111/apt.17343. Aliment Pharmacol Ther. 2023. PMID: 36786459 No abstract available.
-
Letter: the diagnostic value of ultrasound-based versus CT-based sarcopenia measurement in cirrhosis - authors' reply.Aliment Pharmacol Ther. 2023 Mar;57(5):593-594. doi: 10.1111/apt.17398. Aliment Pharmacol Ther. 2023. PMID: 36786465 No abstract available.
Similar articles
-
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent.Eur J Gastroenterol Hepatol. 2013 Jan;25(1):85-93. doi: 10.1097/MEG.0b013e328359a759. Eur J Gastroenterol Hepatol. 2013. PMID: 23011041
-
Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: Long-term patency and clinical outcome results.Eur Radiol. 2017 May;27(5):1795-1803. doi: 10.1007/s00330-016-4570-5. Epub 2016 Sep 15. Eur Radiol. 2017. PMID: 27629421
-
Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents.Scand J Gastroenterol. 2004 Oct;39(10):994-9. doi: 10.1080/00365520410003443. Scand J Gastroenterol. 2004. PMID: 15513340
-
Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: An update of the evidence and future directions.World J Gastroenterol. 2021 Nov 28;27(44):7612-7624. doi: 10.3748/wjg.v27.i44.7612. World J Gastroenterol. 2021. PMID: 34908802 Free PMC article. Review.
-
Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review.J Dig Dis. 2021 Sep;22(9):506-519. doi: 10.1111/1751-2980.13035. Epub 2021 Sep 3. J Dig Dis. 2021. PMID: 34323378 Review.
Cited by
-
Adverse events after the transjugular intrahepatic portal shunt are linked to serum metabolomic changes following the procedure.Front Mol Biosci. 2023 May 15;10:1168782. doi: 10.3389/fmolb.2023.1168782. eCollection 2023. Front Mol Biosci. 2023. PMID: 37255539 Free PMC article.
-
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Nutrition in Liver Cirrhosis Patients: A Systematic Review.Nutrients. 2023 Mar 27;15(7):1617. doi: 10.3390/nu15071617. Nutrients. 2023. PMID: 37049459 Free PMC article.
-
Role of Machine Learning-Based CT Body Composition in Risk Prediction and Prognostication: Current State and Future Directions.Diagnostics (Basel). 2023 Mar 3;13(5):968. doi: 10.3390/diagnostics13050968. Diagnostics (Basel). 2023. PMID: 36900112 Free PMC article. Review.
-
The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.Liver Int. 2021 Dec;41(12):2965-2973. doi: 10.1111/liv.15060. Epub 2021 Sep 28. Liver Int. 2021. PMID: 34543504 Free PMC article.
-
Effect of adipose-related parameters on mortality in patients with liver cirrhosis: a meta-analysis.Ann Med. 2025 Dec;57(1):2473627. doi: 10.1080/07853890.2025.2473627. Epub 2025 Mar 4. Ann Med. 2025. PMID: 40038873 Free PMC article.
References
REFERENCES
-
- Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol. 2013;25:85-93.
-
- Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl. 2017;23:1451-1464.
-
- Durand F, Buyse S, Francoz C, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 2014;60:1151-1157.
-
- Merli M, Giusto M, Gentili F, et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int. 2010;30:208-214.
-
- Golse N, Bucur PO, Ciacio O, et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. Liver Transpl. 2017;23:143-154.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical